In acute myeloid leukaemia with a confirmed FLT3-ITD or FLT3-TKD mutation, completing induction is only the first step. The consolidation phase that follows has its own dedicated protocol — distinct from induction — and determining the appropriate approach requires attention to the patient's mutation status, response to induction, and transplant eligibility.
Patient profile: Acute myeloid leukaemia with FLT3-ITD or FLT3-TKD mutation (allelic ratio ≥0.05); not therapy-related AML and not AML with myelodysplasia-related changes.
Previous induction: 7+3+midostaurin (cytarabine plus daunorubicin plus midostaurin). The induction goal was achievement of complete remission or complete remission with incomplete haematological recovery (CR/CRi) — defined as fewer than 5% blasts in the bone marrow, assessed between day 14 and day 21. This consolidation protocol represents the structured next step following that induction.
Consolidation in this setting involves midostaurin combined with consolidation chemotherapy. Beyond the chemotherapy backbone, the protocol addresses the role of allogeneic haematopoietic cell transplantation for eligible patients — the full algorithm, cycle structure, and decision points are detailed in the complete protocol.